Quarterly ResultMay 12, 2026, 04:17 PM
Palisade Bio to Start PALI-2108 Phase 2 UC Trial 3Q 2026; Q1 Net Loss $9.6M
AI Summary
Palisade Bio reported its first quarter 2026 financial results and provided an update on its lead program, PALI-2108. The company plans to initiate a Phase 2 Ulcerative Colitis (UC) trial in Q3 2026 and a Phase 2 Crohn's Disease (CD) trial in Q1 2027, building on positive Phase 1a/b data. For Q1 2026, Palisade Bio reported a net loss of $9.6 million, with increased R&D and G&A expenses. The company maintains a strong balance sheet with $132.6 million in cash, expected to fund operations through key clinical readouts in 2027 and 2028.
Key Highlights
- Phase 2 Ulcerative Colitis (UC) trial for PALI-2108 expected to commence 3Q 2026.
- Phase 2 Crohn's Disease (CD) trial for PALI-2108 targeted for Q1 2027.
- Research and development expenses increased to $6.4 million in Q1 2026 from $1.0 million in Q1 2025.
- General and administrative expenses rose to $4.4 million in Q1 2026 from $1.4 million in Q1 2025.
- Net loss for Q1 2026 was $9.6 million, compared to $2.2 million in Q1 2025.
- Cash and cash equivalents stood at $132.6 million as of March 31, 2026.
- Cash runway expected to fund operations through Phase 2 UC readout (2H 2027) and CD readout (early 2028).
- PALI-2108 demonstrated favorable safety, tolerability, and target engagement in Phase 1a/b trials.
Price Impact
More from PALI